Long-term treatment with dupilumab, an injection therapy approved for certain inflammatory conditions, reduces disease severity, promotes wound healing, and eases itch among people with different subtypes of dystrophic epidermolysis bullosa (DEB), including severe DEB. In their real-world study, researchers also reported that DEB patients treated with dupilumab experienced sustained…